逆转炎性衰老:丙型肝炎治愈对生物学年龄的长期影响
研究纳入54例经直接抗病毒药物(DAA)治疗获得持续病毒学应答(SVR)的慢性丙型肝炎患者,在治疗开始、治疗结束和长期随访(中位96周)三个时间点检测外周血单个核细胞DNA甲基化,用Horvath时钟计算表观遗传年龄加速(EAA)。基线时HCV患者EAA为3.12年,年龄性别匹配参照组为-2.61年(p<0.00003);长期随访EAA降至1.37年,仅治疗结束至随访间下降显著(p=0.01)。8例SVR后发生肝细胞癌者EAA最高且无逆转证据。
要点
- 慢性HCV感染患者基线EAA为3.12年,显著高于匹配参照组的-2.61年(p<0.00003)。
- DAA治愈后长期随访EAA降至1.37年,仅治疗结束至随访间下降显著(p=0.01)。
- SVR后发生肝细胞癌的8例患者EAA最高,未见EAA逆转证据。
核心结论
- HCV清除可导致「逆转炎性衰老」,表观遗传改变或生物学年龄加速在原则上可逆但需要时间。
- SVR后缺乏EAA逆转可能与肝细胞癌发生相关。
- 数据支持生物学年龄作为SVR后HCV后遗症的潜在生物标志物。
研究设计与样本
- 纳入54例在三家中心经DAA治疗获得SVR的慢性丙型肝炎患者,在DAA治疗开始、治疗结束和长期随访(治疗结束后中位96周)三个时间点采集样本。
- 在外周血单个核细胞(PBMC)中检测全基因组DNA甲基化状态,使用Horvath时钟计算表观遗传年龄加速(EAA)。
主要发现
- 基线时HCV患者EAA为3.12年,年龄和性别匹配的参照组为-2.61年(p<0.00003)。
- HCV清除导致所有患者组DNA甲基化长期显著增加,以高甲基化CpG为主。
- 长期随访时EAA降至1.37年,EAA下降仅在治疗结束与随访之间具有统计学显著性(p=0.01)。
- 8例SVR后发生肝细胞癌的个体EAA最高,且未见SVR后逆转的证据。
临床怎么用
- 作者认为,生物学年龄可能成为未来个体化临床评估的基石,因为它能更好地反映患者数十年来的生活方式和环境暴露。
- 作者提出,未来或可探索生物学年龄如何改进目前考虑实际年龄的临床风险评分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Chronic hepatitis C virus (HCV) infection can be cured with direct-acting antivirals (DAAs). However, not all sequelae of chronic hepatitis C appear to be completely reversible after sustained virologic response (SVR). Recently, chronic viral infections have been shown to be associated with biological age acceleration defined by the epigenetic clock. The aim of this study was to investigate whether chronic HCV infection is associated with epigenetic changes and biological age acceleration and whether this is reversible after SVR. METHODS: We included 54 well-characterized individuals with chronic hepatitis C who achieved SVR after DAA therapy at three time points: DAA treatment initiation, end of treatment, and long-term follow-up (median 96 weeks after end of treatment). Genome-wide DNA methylation status was determined in peripheral blood mononuclear cells (PBMCs) and used to calculate epigenetic age acceleration (EAA) using Horvath's clock. RESULTS: Individuals with HCV had an overall significant EAA of 3.12 years at baseline compared with -2.61 years in the age- and sex-matched reference group (p <0.00003). HCV elimination resulted in a significant long-term increase in DNA methylation dominated by hypermethylated CpGs in all patient groups. Accordingly, EAA decreased to 1.37 years at long-term follow-up. The decrease in EAA was significant only between the end of treatment and follow-up (p = 0.01). Interestingly, eight individuals who developed hepatocellular carcinoma after SVR had the highest EAA and showed no evidence of reversal after SVR. CONCLUSIONS: Our data contribute to the understanding of the biological impact of HCV elimination after DAA therapy and demonstrate that HCV elimination can lead to "reverse inflammaging". In addition, our data support the potential use of biological age as a biomarker for HCV sequelae after SVR. IMPACT AND IMPLICATIONS: Chronic hepatitis C virus infection is now curable with direct-acting antivirals, but it remains unclear whether hepatitis C sequelae are fully reversible after viral elimination. Our results suggest that epigenetic changes or acceleration of biological age are reversible in principle, but this requires time, while a lack of reversibility appears to be associated with the development of hepatocellular carcinoma. While most clinical risk scores now take chronological age into account, it may be worthwhile to explore how biological age might improve these scores in the future. Biological age may be a cornerstone for the individualized clinical assessment of patients in the future, as it better reflects patients' lifestyle and environmental exposures over decades.
引用
- Oltmanns C, Liu Z, Mischke J, et al. Reverse inflammaging: Long-term effects of HCV cure on biological age. J Hepatol. 2022. PMID: 36152762. doi:10.1016/j.jhep.2022.08.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。